Cargando…

The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster

Wuwei Qingzuo San (WWQZS), as a renowned traditional Mongolian patent medicine approved by Chinese State Food and Drug Administration, is used to treat hyperlipidemia, indigestion, and other ailments related to disorder of production of essence and phlegm, a typical abnormal metabolism of blood in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianliang, Wang, Chaolu, Song, Lin, Cai, Shuzhen, Li, Zhiyong, Tu, Ya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212318/
https://www.ncbi.nlm.nih.gov/pubmed/32454862
http://dx.doi.org/10.1155/2020/5369025
_version_ 1783531594993106944
author Li, Jianliang
Wang, Chaolu
Song, Lin
Cai, Shuzhen
Li, Zhiyong
Tu, Ya
author_facet Li, Jianliang
Wang, Chaolu
Song, Lin
Cai, Shuzhen
Li, Zhiyong
Tu, Ya
author_sort Li, Jianliang
collection PubMed
description Wuwei Qingzuo San (WWQZS), as a renowned traditional Mongolian patent medicine approved by Chinese State Food and Drug Administration, is used to treat hyperlipidemia, indigestion, and other ailments related to disorder of production of essence and phlegm, a typical abnormal metabolism of blood in traditional Mongolian medicine. A combination of network pharmacology and validation experiments in hyperlipidemia hamster is used to understand the potential mechanism of WWQZS for hypolipidemic effects, further for an integrated concept of traditional theory, bioactive constituents, and molecular mechanism for TMM. Through network pharmacology, we obtained 212 components, 219 predicted targets, and 349 known hyperlipidemia-related targets form public database and used Metascape to carry out enrichment analysis of 43 potential and 45 candidate targets to imply numerous BP concerned with metabolism of lipid, regulation of kinases and MF related to lipid binding, phosphatase binding, and receptor ligand activity that are involved in anti-hyperlipidemia. In addition, KEGG pathways that explicated hypolipidemic effect were involved in pathways including metabolism associated with kinase function according to MAPK signaling pathway, AMPK signaling pathway, and PI3K-Akt signaling pathway. Meanwhile, in HFD-induced hamster model, WWQZS could significantly reduce TC and ALT and help decrease TG, LDL-C as well; liver pathological section implied that WWQZS could relieve liver damage and lipid accumulation. Western blot indicated that WWQZS may upregulate CYP7A1 and activate AMPK to suppress the expression of HMGCR in livers. In conclusion, our results suggest that WWQSZS plays important dual hypolipidemic and liver-protective role in livers in HFD-induced hamster model. Through this research, a new reference is also provided to other researches in the study of ethnopharmacology.
format Online
Article
Text
id pubmed-7212318
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-72123182020-05-23 The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster Li, Jianliang Wang, Chaolu Song, Lin Cai, Shuzhen Li, Zhiyong Tu, Ya Evid Based Complement Alternat Med Research Article Wuwei Qingzuo San (WWQZS), as a renowned traditional Mongolian patent medicine approved by Chinese State Food and Drug Administration, is used to treat hyperlipidemia, indigestion, and other ailments related to disorder of production of essence and phlegm, a typical abnormal metabolism of blood in traditional Mongolian medicine. A combination of network pharmacology and validation experiments in hyperlipidemia hamster is used to understand the potential mechanism of WWQZS for hypolipidemic effects, further for an integrated concept of traditional theory, bioactive constituents, and molecular mechanism for TMM. Through network pharmacology, we obtained 212 components, 219 predicted targets, and 349 known hyperlipidemia-related targets form public database and used Metascape to carry out enrichment analysis of 43 potential and 45 candidate targets to imply numerous BP concerned with metabolism of lipid, regulation of kinases and MF related to lipid binding, phosphatase binding, and receptor ligand activity that are involved in anti-hyperlipidemia. In addition, KEGG pathways that explicated hypolipidemic effect were involved in pathways including metabolism associated with kinase function according to MAPK signaling pathway, AMPK signaling pathway, and PI3K-Akt signaling pathway. Meanwhile, in HFD-induced hamster model, WWQZS could significantly reduce TC and ALT and help decrease TG, LDL-C as well; liver pathological section implied that WWQZS could relieve liver damage and lipid accumulation. Western blot indicated that WWQZS may upregulate CYP7A1 and activate AMPK to suppress the expression of HMGCR in livers. In conclusion, our results suggest that WWQSZS plays important dual hypolipidemic and liver-protective role in livers in HFD-induced hamster model. Through this research, a new reference is also provided to other researches in the study of ethnopharmacology. Hindawi 2020-05-10 /pmc/articles/PMC7212318/ /pubmed/32454862 http://dx.doi.org/10.1155/2020/5369025 Text en Copyright © 2020 Jianliang Li et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Jianliang
Wang, Chaolu
Song, Lin
Cai, Shuzhen
Li, Zhiyong
Tu, Ya
The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster
title The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster
title_full The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster
title_fullStr The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster
title_full_unstemmed The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster
title_short The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster
title_sort potential mechanism of wuwei qingzhuo san against hyperlipidemia based on tcm network pharmacology and validation experiments in hyperlipidemia hamster
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212318/
https://www.ncbi.nlm.nih.gov/pubmed/32454862
http://dx.doi.org/10.1155/2020/5369025
work_keys_str_mv AT lijianliang thepotentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT wangchaolu thepotentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT songlin thepotentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT caishuzhen thepotentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT lizhiyong thepotentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT tuya thepotentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT lijianliang potentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT wangchaolu potentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT songlin potentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT caishuzhen potentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT lizhiyong potentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster
AT tuya potentialmechanismofwuweiqingzhuosanagainsthyperlipidemiabasedontcmnetworkpharmacologyandvalidationexperimentsinhyperlipidemiahamster